CN1125082C - 人类趋化因子β－8,趋化因子β－1和巨噬细胞炎性蛋白－4 - Google Patents

人类趋化因子β－8,趋化因子β－1和巨噬细胞炎性蛋白－4 Download PDF

Info

Publication number
CN1125082C
CN1125082C CN95197892A CN95197892A CN1125082C CN 1125082 C CN1125082 C CN 1125082C CN 95197892 A CN95197892 A CN 95197892A CN 95197892 A CN95197892 A CN 95197892A CN 1125082 C CN1125082 C CN 1125082C
Authority
CN
China
Prior art keywords
nucleic acid
seq
continuous bases
polypeptide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95197892A
Other languages
English (en)
Chinese (zh)
Other versions
CN1186501A (zh
Inventor
C·A·罗森
S·M·卢本
李浩东
M·D·艾德姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of CN1186501A publication Critical patent/CN1186501A/zh
Application granted granted Critical
Publication of CN1125082C publication Critical patent/CN1125082C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN95197892A 1995-05-05 1995-06-23 人类趋化因子β－8,趋化因子β－1和巨噬细胞炎性蛋白－4 Expired - Fee Related CN1125082C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44688195A 1995-05-05 1995-05-05
US08/446,881 1995-05-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA021471495A Division CN1515672A (zh) 1995-05-05 1995-06-23 人类趋化因子β-8,趋化因子β-1和巨噬细胞炎性蛋白-4

Publications (2)

Publication Number Publication Date
CN1186501A CN1186501A (zh) 1998-07-01
CN1125082C true CN1125082C (zh) 2003-10-22

Family

ID=23774170

Family Applications (2)

Application Number Title Priority Date Filing Date
CN95197892A Expired - Fee Related CN1125082C (zh) 1995-05-05 1995-06-23 人类趋化因子β－8,趋化因子β－1和巨噬细胞炎性蛋白－4
CNA021471495A Pending CN1515672A (zh) 1995-05-05 1995-06-23 人类趋化因子β-8,趋化因子β-1和巨噬细胞炎性蛋白-4

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA021471495A Pending CN1515672A (zh) 1995-05-05 1995-06-23 人类趋化因子β-8,趋化因子β-1和巨噬细胞炎性蛋白-4

Country Status (8)

Country Link
EP (1) EP0871672A4 (de)
JP (2) JPH11505417A (de)
KR (1) KR19990008335A (de)
CN (2) CN1125082C (de)
AU (1) AU3134695A (de)
CA (1) CA2220123A1 (de)
MX (1) MX9708537A (de)
WO (1) WO1996034891A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US6623942B2 (en) 1994-03-08 2003-09-23 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polynucleotides
EA199800352A1 (ru) * 1995-09-29 1998-12-24 Смитклайн Бичам Корпорейшн ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
ATE317012T1 (de) * 1996-04-30 2006-02-15 Pharis Biotec Gmbh Chemokine vom cc-typ
NZ506135A (en) * 1996-09-30 2002-11-26 Human Genome Sciences Inc Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis
US5912327A (en) * 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
DK1015477T3 (da) 1997-05-30 2011-02-07 Human Genome Sciences Inc 32 humane sekreterede proteiner
WO1999023105A1 (en) 1997-11-03 1999-05-14 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
KR19990042713A (ko) * 1997-11-27 1999-06-15 허일섭 사람에서 분리한 c 6 베타-케모카인 lkn-1의 cdna 및 재조합 lkn-1의 제조방법
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU4818599A (en) * 1998-07-06 2000-01-24 Schering Corporation Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12),md-1, md2 and cyclin e2, related reagents and methods
EP0974357A1 (de) 1998-07-16 2000-01-26 Schering-Plough Chemokine als Adjuvantien der Immunantwort
US6495128B1 (en) 1998-11-10 2002-12-17 Human Genome Sciences, Inc. Human chemokine β-7 deletion and substitution proteins
JP2003516934A (ja) * 1999-10-14 2003-05-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒト骨髄前駆細胞阻害性因子−１（ｍｐｉｆ−１）を用いる、細胞、組織および器官の損傷を処置または予防する方法
WO2001031016A2 (en) * 1999-10-25 2001-05-03 Euroscreen S.A. Processed human chemokines phc-1 and phc-2
EP1167527A1 (de) * 2000-06-22 2002-01-02 Euroscreen S.A. Prozessierte Menschliche Chemokine: PHC-1 und PHC-2
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
AU2001271621A1 (en) 2000-06-28 2002-01-08 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
AU8847801A (en) 2000-08-25 2002-03-04 Basf Plant Science Gmbh Plant polynucleotides encoding novel prenyl proteases
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
EP1692171B1 (de) 2003-12-05 2009-06-03 Oxagen Limited Die aktivität von ccrl2 modulierende mittel und verfahren zu deren anwendung
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2054437A2 (de) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin-fusionsproteine
WO2012116453A1 (en) 2011-03-03 2012-09-07 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
AU2013289881B2 (en) 2012-07-13 2018-01-18 Zymeworks Bc Inc. Multivalent heteromultimer scaffold design and constructs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87100135A (zh) * 1986-01-08 1987-09-02 罗讷—布郎克农业化学公司 卤芳香基腈降解基因，其用途以及含该基因的细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005198A1 (en) * 1990-09-14 1992-04-02 Chiron Corporation EXPRESSION OF MACROPHAGE INDUCIBLE PROTEINS (MIPs) IN YEAST CELLS
CN1143894A (zh) * 1993-12-22 1997-02-26 人类基因组科学公司 巨噬细胞炎性蛋白-3，-4和-1r
CA2179638A1 (en) * 1993-12-24 1995-07-06 Peter Schulz-Knappe Human circulating cytokine cc-1
US5602008A (en) * 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
US5874211A (en) * 1995-04-13 1999-02-23 Incyte Pharmaceuticals, Inc. Chemokine expressed in eosinophils

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87100135A (zh) * 1986-01-08 1987-09-02 罗讷—布郎克农业化学公司 卤芳香基腈降解基因，其用途以及含该基因的细胞

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THEJOURNALOFNIOLOGICALCHEMISTRY,269(41) 1994-10-14 Chang,et,al,Cloning,and,Characterization,of,the,Human,Neutrophil-activating,Peptide,(ENA-78)Gene" *

Also Published As

Publication number Publication date
CN1515672A (zh) 2004-07-28
WO1996034891A1 (en) 1996-11-07
CN1186501A (zh) 1998-07-01
EP0871672A4 (de) 1999-05-12
JPH11505417A (ja) 1999-05-21
KR19990008335A (ko) 1999-01-25
AU3134695A (en) 1996-11-21
CA2220123A1 (en) 1996-11-07
JP2003102486A (ja) 2003-04-08
MX9708537A (es) 1998-02-28
EP0871672A1 (de) 1998-10-21

Similar Documents

Publication Publication Date Title
CN1125082C (zh) 人类趋化因子β－8,趋化因子β－1和巨噬细胞炎性蛋白－4
CN1267550C (zh) 血管内皮生长因子2
CN1107072C (zh) 编程性细胞死亡诱导分子ⅱ
CN1186518A (zh) 人血管内皮生长因子2
CN1190991A (zh) 人类趋化因子β－11和人类趋化因子α－1
CN1146442C (zh) 作为抗肿瘤剂的淋巴毒素-α/β复合体和抗淋巴毒素-β受体抗体
CN1143894A (zh) 巨噬细胞炎性蛋白-3，-4和-1r
CN1110323A (zh) 新多肽和编码它们的脱氧核糖核酸
CN1282372A (zh) 哺乳动物细胞因子样多肽－10
CN1217024A (zh) 趋化因子α－2
CN1211487C (zh) 链球菌毒素a突变体及其使用方法
CN1213401A (zh) Exodus化学激活素物质及方法
CN1553955A (zh) 血小板糖蛋白IBα融合多肽和其利用的方法
CN1620466A (zh) 胱氨酸结折迭蛋白质
CN1639569A (zh) 诱导免疫应答的方法和组合物
CN1192751A (zh) 单核细胞趋化蛋白－4
CN1546528A (zh) 激肽原第五结构域-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
CN1033070A (zh) 修饰的血纤维蛋白溶酶原激活剂
CN1240836C (zh) 转化生长因子αHI
CN1109505A (zh) α/β-干扰素结合蛋白，制法及用途
CN1157410C (zh) 人g蛋白偶联受体(hetgq23)
CN1414020A (zh) 成纤维细胞生长因子11的抗体、拮抗剂及激动剂
CN1319137A (zh) 角质形成细胞衍生的干扰素
CN1282371A (zh) 从人分离的编码C6β－趋化因子Lkn－1的cDNA
CN1566155A (zh) 抗sars病毒的单克隆抗体、其编码序列及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1016190

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee